Cellectar Biosciences, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. MARKET FOR COMMON EQUITY Market Information Our common stock is listed on the Nasdaq Capital Market under the ticker symbol CLRB. On February 24, 2023 there were 98 holders of record of our common stock. This number does not include stockholders for whom shares were held in a “nominee” or “street” name. We have not declared or paid any cash dividends on our common stock and do not anticipate declaring or paying any cash dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the continued development of our business. Our transfer agent and registrar is American Stock Transfer and Trust Company, 6201 15 th Avenue, Brooklyn, NY 11219. Equity compensation plans The following table provides information as of December 31, 2022, regarding shares authorized for issuance under our equity compensation plans, including individual compensation arrangements. Equity compensation plan information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of shares ​ ​ ​ ​ Weighted-average ​ remaining available for ​ ​ Number of shares to ​ exercise price of ​ future issuance under ​ ​ be issued upon ​ outstanding ​ equity compensation plans ​ ​ exercise of outstanding ​ options ​ (excluding shares reflected Plan category ​ options and rights (#) ​ and rights ($) ​ in column (a)) (#) ​ (a) ​ (b) (c) ​ Equity compensation plans approved by stockholders 630,132 ​ $ 13.74 635,753 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity compensation plans not approved by stockholders 116,125 ​ $ 12.69 n/a ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total 746,257 ​ $ 13.57 635,753 ​ ​ 56 Table of Contents Recent Sales of Unregistered Equity Securities On October 20, 2022, we entered into a Securities Purchase Agreement with certain purchasers named therein, pursuant to which we agreed to issue and sell additional securities in an SEC-registered transaction, common warrants to purchase up to an aggregate of 3,275,153 shares of our common stock. On the same day we entered into a Private Placement Purchase Agreement with certain purchasers named therein, pursuant to which we agreed to issue and sell pre-funded warrants to purchase up to an aggregate of 1,875,945 shares of our common stock and common warrants to purchase up to an aggregate of 1,875,945 shares of our common stock. ​ ​ Item 6. [Reserved]